Browsing by Author Cunningham, Evan B.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 3 of 3
Issue DateTitleAuthor(s)Citation
2017Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE studyWeltman, Martin; Amin, Janaki; Backmund, Markus; Bruggmann, Philip; Conway, Brian; Cunningham, Evan B.; Dalgard, Olav; et al, Various; Foster, Graham R; Hajarizadeh, Behzad; Hellard, Margaret; Nepean Clinical School: MedicineAdherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study, BMC Infectious Diseases, vol.17, 1, 2017,pp 1-12
2017Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE studyWeltman, Martin; Backmund, Markus; Bourgeois, Stefan; Bruggmann, Philip; Bruneau, Julie; Conway, Brian; Cunningham, Evan B.; Dunlop, Adrian; et al, Various; Hajarizadeh, Behzad; Midgard, Havard; Nepean Clinical School: MedicineChanges in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study, International Journal of Drug Policy, vol.47, N/A, 2017,pp 230-238
2017Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE studyWeltman, Martin; Backmund, Markus; Bruggmann, Philip; Conway, Brian; Cunningham, Evan B.; Dalgard, Olav; et al, Various; Foster, Graham R; Grebely, Jason; Hajarizadeh, Behzad; Robaeys, Geert; Nepean Clinical School: MedicineEfficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study, International Journal of Drug Policy, vol.47, N/A, 2017,pp 177-186